OBJECTIVE: Sex hormones are thought to play an important role in the pathophysiology of depressive disorders in women. This study assessed the associations of total testosterone (T), bioavailable T, estradiol, dehydroepiandrosterone, and sex hormone-binding globulin (SHBG) with depressive symptoms stratified on postmenopausal stage to determine whether the associations were strongest for early postmenopausal women. METHODS: Women (N = 1,824) free of depressive symptoms at baseline (2000-2002) in the Multiethnic Study of Atherosclerosis were categorized into tertiles of years postmenopause: T1, 0 to 10 years; T2, 11 to 20 years; and T3, 21 to 58 years. Multivariable-adjusted relative risks (RRs) and 95% CIs were computed for the incidence of depressive symptoms, as defined by a score of 16 or higher on the Center for Epidemiologic Studies Depression scale at examination 3 (2004-2005). RESULTS: In analysis including all sex hormones, the RR for incident depressive symptoms associated with 1 unit higher log total T was 0.57 (P = 0.13), with log estradiol was 0.78 (P = 0.04), with log SHBG was 1.84 (P = 0.003), and with log dehydroepiandrosterone was 1.45 (P = 0.08) in T1. Without adjustment for SHBG, the RR for log bioavailable T was 0.16 (P = 0.04). However, in T2 and T3, there were no meaningful associations of hormone or SHBG levels with incident depressive symptoms. When stratified by HT use, results were consistent for HT users but attenuated for HT nonusers. CONCLUSIONS: In early postmenopausal women, sex hormones were associated with incident depressive symptoms.
OBJECTIVE: Sex hormones are thought to play an important role in the pathophysiology of depressive disorders in women. This study assessed the associations of total testosterone (T), bioavailable T, estradiol, dehydroepiandrosterone, and sex hormone-binding globulin (SHBG) with depressive symptoms stratified on postmenopausal stage to determine whether the associations were strongest for early postmenopausal women. METHODS:Women (N = 1,824) free of depressive symptoms at baseline (2000-2002) in the Multiethnic Study of Atherosclerosis were categorized into tertiles of years postmenopause: T1, 0 to 10 years; T2, 11 to 20 years; and T3, 21 to 58 years. Multivariable-adjusted relative risks (RRs) and 95% CIs were computed for the incidence of depressive symptoms, as defined by a score of 16 or higher on the Center for Epidemiologic Studies Depression scale at examination 3 (2004-2005). RESULTS: In analysis including all sex hormones, the RR for incident depressive symptoms associated with 1 unit higher log total T was 0.57 (P = 0.13), with log estradiol was 0.78 (P = 0.04), with log SHBG was 1.84 (P = 0.003), and with log dehydroepiandrosterone was 1.45 (P = 0.08) in T1. Without adjustment for SHBG, the RR for log bioavailable T was 0.16 (P = 0.04). However, in T2 and T3, there were no meaningful associations of hormone or SHBG levels with incident depressive symptoms. When stratified by HT use, results were consistent for HT users but attenuated for HT nonusers. CONCLUSIONS: In early postmenopausal women, sex hormones were associated with incident depressive symptoms.
Authors: Joyce T Bromberger; Laura L Schott; Howard M Kravitz; Maryfran Sowers; Nancy E Avis; Ellen B Gold; John F Randolph; Karen A Matthews Journal: Arch Gen Psychiatry Date: 2010-06
Authors: Zsófia Herbert; Susanne Göthe; Jack D Caldwell; Hans-Gert Bernstein; Christian Melle; Ferdinand von Eggeling; John Lewis; Gustav F Jirikowski Journal: Neuroendocrinology Date: 2005-09-07 Impact factor: 4.914
Authors: Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian Journal: J Clin Endocrinol Metab Date: 2010-06-21 Impact factor: 5.958
Authors: H G Burger; E C Dudley; J L Hopper; N Groome; J R Guthrie; A Green; L Dennerstein Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: R Calderon-Margalit; S M Schwartz; M F Wellons; C E Lewis; M L Daviglus; P J Schreiner; O D Williams; B Sternfeld; J J Carr; D H O'Leary; S Sidney; Y Friedlander; D S Siscovick Journal: J Clin Endocrinol Metab Date: 2010-06-16 Impact factor: 5.958
Authors: Kevin M Hellman; Folabomi A Oladosu; Ellen F Garrison; Genevieve E Roth; Katlyn E Dillane; Frank F Tu Journal: Mol Pain Date: 2021 Jan-Dec Impact factor: 3.395
Authors: Cielo García-Montero; Miguel A Ortega; Miguel Angel Alvarez-Mon; Oscar Fraile-Martinez; Adoración Romero-Bazán; Guillermo Lahera; José Manuel Montes-Rodríguez; Rosa M Molina-Ruiz; Fernando Mora; Roberto Rodriguez-Jimenez; Javier Quintero; Melchor Álvarez-Mon Journal: Nutrients Date: 2022-03-06 Impact factor: 5.717